KYTX.US Kyverna Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
5.05 USD
Close of Nov 15, 2026
4.50 13.67
Market cap
USD 319M
P/E
-
P/B
2.40x
ROE
-120.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KYTX.US undervalued?

Graham number

The Graham number of Kyverna Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kyverna Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Kyverna Therapeutics, Inc. Common Stock yet.

Kyverna Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CA…

Full company profile